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Abstract 
The evidence in the medical literature on the efficacy 
and safety of rituximab therapy for primary glomeru-
lonephritis is limited and controversial. We describe two 
male Caucasian patients with rapidly progressive kidney 
failure due to primary proliferative glomerulonephritis. 
Both of them received high-dose intravenous corti-
costeroids and oral cyclophosphamide with limited 
benefit. The first patient (hepatitis C virus-negative 
mixed cryoglobulinemia) underwent plasma-exchange 
with intravenous immunoglobulins; he showed signi-
ficant benefit on kidney function (he became dialysis 
independent with serum creatinine going back to 
1.6 mg/dL) after one rituximab pulse even if urinary 
abnormalities were still present. No improvement 
in renal function or urinary changes occurred in the 
second patient. Both these individuals developed sepsis 
over the follow-up, the first patient died two months 
after rituximab therapy. This report is in keeping with 
the occurrence of severe infections after rituximab 
therapy in patients with renal impairment at baseline 
and concomitant high-dose steroids. 
Key words: Chronic kidney disease; Cryoglobulinemic 
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Core tip: A small but growing body of evidence is 
emerging on the efficacy and safety of rituximab 
therapy for primary glomerulonephritis. Various authors 
have claimed that rituximab for glomerular diseases is 
effective and has minimal adverse effects. We report 
on two male Caucasian patients who were refractory to 
conventional immunosuppressive therapy; each of them 
received one rituximab pulse and developed sepsis 
over the follow-up, the first patient died two months 
after rituximab therapy. The risks (and the predictive 
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factors) of severe infections in kidney patients on 
rituximab therapy are unclear and appear an area of 
active research. 
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INTRODUCTION
Primary glomerulonephritis (GN) remains an important 
cause of end-stage kidney disease. Preliminary trials 
have recently shown the efficacy of rituximab for adult-
onset primary GN[1]; rituximab being a genetically 
chimeric monoclonal antibody directed to CD20 antigen, 
a B-cell-specific transmembrane found on immature and 
mature cells, as well as on malignant B cells. Following 
treatment with rituximab (RTX), B-cells are prevented 
from proliferating, and undergo apoptosis and lysis 
through complement-dependent and - independent 
mechanisms. B-cell depletion usually persists for 6-9 mo 
in around 80% of patients, but the degree of depletion 
is greatly variable. Rituximab is currently approved 
for treating various malignancies including B cell non-
Hodgkin’s lymphoma and chronic lymphocytic leukemia; 
also, it has been licensed for refractory rheumatoid 
arthritis, granulomatosis with polyangiitis (Wegener’s 
granulomatosis) and microscopic polyangiitis. Rituximab 
was expected to inhibit the production of autoantibodies 
involved in the pathogenesis of the disease without 
the toxicity of nonspecific immunosuppression. It has 
been the first monoclonal employed for the treatment 
of glomerular diseases and has been initially used for 
patients with membranous nephropathy but its use 
has rapidly spread to other glomerular diseases[1]. 
Membranous nephropathy and membranoproliferative 
GN are characterized by glomerular deposition of immune 
complexes; a crucial role of B cells in membranous 
(MN) and membranoproliferative glomerulonephritis 
pathogenesis through autoantibody production and 
antigen presentation has been mentioned. A small but 
growing body of literature is emerging on the benefits 
of rituximab in MN and membranoproliferative glomerul-
onephritis as primary treatment or as treatment of 
lesions refractory to other immunomodulatory regimens. 
In this setting, the drug appears to be well tolerated with 
small adverse events (Table 1)[2-8].
We report here our experience on rituximab use 
in two patients with progressive kidney failure due 
to primary proliferative GN. Both of them received 
conventional immunosuppressive therapy with limited 
benefit on urinary and biochemical abnormalities; 
then, they underwent one RTX pulse but developed 
sepsis over the follow-up. A brief review on the safety 
and efficacy of rituximab for primary GN has been also 
added.
CASE REPORT
Patient 1
A 51-year-old Caucasian male patient was admitted to 
hospital for two-week’s duration of abdominal pain with 
vomiting and diarrhoea. His medical history included 
arterial hypertension and symptomatic hepatitis C 
virus (HCV)-negative mixed cryoglobulinemia (since 
three years) with recurrent purpura and peripheral 
neuropathy at the lower extremities. Skin biopsy had 
shown leukocytoclastic vasculitis whereas neurological 
evaluation had revealed mono-neuritis at the left 
foot with axonal ischemic damage, probably related 
to cryoprecipitable immune complexes in the vasa 
nervorum. He had received low dose oral corticosteroids 
and azathioprine with partial control of cutaneous and 
neurological abnormalities. A bone marrow biopsy had 
reported no evidence of malignant lymphoma, and a 
small expansion of B lymphocytes (10%-15%).
A physical examination showed bilateral edema and 
hypertension (180/100 mmHg), purpuric rash with 
ulcers at the legs (Figure 1); no bowel movements were 
apparent from the clinical standpoint, this being confirmed 
by an abdomen X-ray. An ultrasound scan of the 
abdomen showed normal sized kidneys bilaterally, with 
normal echotexture. At presentation (Table 1), abnormal 
laboratory results included serum creatinine level of 2.5 
mg/dL, proteinuria, 3.6 g/24 h, and hypoalbuminemia 
(2 g/L). Other pertinent chemistries were: positive 
cryoglobulins, with a cryocrit of 3% (polyclonal IgG 
and monoclonal IgMk), elevated rheumatoid factor 
(148 IU/mL) and hypocomplementemia. Serology 
was negative for hepatitis B virus (HBV), HCV and 
human immuno-deficiency virus (HIV) markers, 
polymerase chain reaction tested negative for HCV RNA. 
Repeat urine sediment, analyzed by phase-contrast 
microscopy, showed severe microscopic hematuria (> 
50 erythrocytes/microscopic field), many dysmorphic 
erythrocytes and casts (ialine, granular and red cell 
casts). Bence Jones proteinuria (kappa type) was 
positive. The search for anti-neutrophil cytoplasmic 
antibody (proteinase 3 and myeloperoxidase), anti-
glomerular basement membrane antibody, extractable 
nuclear antigen antibody, antinuclear and anti-double 
stranded DNA tested negative.
Renal biopsy was not performed due to anatomic 
reasons, and a diagnosis of essential MC with rapidly 
progressive renal failure due to nephritic/nephrotic 
syndrome was made. Treatment was initiated with 
intravenous methylprednisolone (600 mg/d for three 
days), oral prednisone (50 mg/d on taper), and oral 
cyclophosphamide (100 mg daily). The progressive 
deterioration of kidney function (serum creatinine raised 
to 6.3 mg/dL, blood urea nitrogen to 279 mg/L) led us 
to make sequential plasma-exchange (nine sessions) 
and high-dose intravenous immunoglobulins (five 
procedures); in addition, hemodialysis was started. We 
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observed healing of skin ulcers and improvement of 
neuropathic pain; GI disorders disappeared but immuno-
suppressive therapy was complicated by Clostridium 
Difficile-positive diarrhea, which was successfully treated 
with oral vancocine. Due to the persistence of severe 
renal failure (serum creatinine of 4.2 mg/dL), he received 
one infusion of RTX (375 mg/m2) off-label (Figure 2); by 
day 6 of the RTX dose, an improvement of urine output 
occurred. Since then, serum creatinine went back to 
1.6 mg/dL, and blood urea nitrogen to 104 mg/dL. At 
discharge from the hospital, his medications included oral 
steroids, rabeprazole, amlodipine, furosemide, calcium 
carbonate, gabapentine, and darboepoetin. 
Two weeks after hospital discharge, serum creatinine 
was 1.76 mg/dL, blood urea nitrogen, 86 mg/dL, 
serum albumin 2.5 g/dL; severe and dysmorphic 
hematuria and non-nephrotic proteinuria (1.43 g/L) 
being still present. Low white blood cell count after RTX 
administration (3.4 × 103/mmc) occurred. According 
to flow cytometry, CD20+ B cells were 19% of total 
peripheral blood lymphocytes (before RTX) and fell to 
1% (after RTX, since day 6) with no increase over the 
following weeks. 
One month later, he became pyrexial with a 
temperature around 38 ℃ and was admitted again to 
the hospital. Pertinent biochemistry included serum 
creatinine (0.8 mg/dL), cryoglobulins and rheumatoid 
factor tested positive. Complete blood count gave 
the following features: white blood cells 2.67 × 103/
mmc, erythrocytes 3.57 × 106/mmc, platelets 209 × 
103/mmc. Flow cytometry: lymphocytes 169/mm3, 
CD3+ cells 142 (83.9%), CD19+ 0 (0%), natural killer 
cells 25 (14.9%). Gamma globulins were 0.16 g/dL 
(3.9%, 11%-18.8%). IgA < 4 mg/dL (70-400), IgG 
84 mg/dL (700-1600), IgM 108 mg/dL (40-230). 
Monoclonal component by serum electrophoresis 
(IgMk + oligoclonal Ig) was again detected. An active 
urinary sediment with non-nephrotic proteinuria (1.21 
g/d) was still present. Sepsis from Enterococcus Spp. 
was identified whereas the chest radiograph reported 
multiple pneumoniae. The culture of the broncho-
alveolare lavage fluid was positive for Candida albicans, 
thus, we initiated intravenous imipenem and antifungal 
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Table 1  Blood chemistries at presentation and over follow-up (patient 1)
Admission Discharge Middle follow-up Final follow-up
Creatinine (0.5-1.2, mg/dL) 2.8 1.59 1.76 0.8
Blood urea nitrogen (8-20, mg/dL) 147 104 86 85
AST (5-32, IU/L) 12 24 27 23
ALT (5-31, IU/L) 9 43 39 7
γGT (5-36, IU/L) 12 44 41 69
Cholinesterasis (5300-12900, IU/L) 3833 2160 2920 3173
Total bilirubin (0.2-1.1, mg/dL) 0.2 0.25 0.22 0.23
Direct bilirubin (0-0.3, mg/dL) 0.09 0.07 0.08 0.16
Total protein (6.6-8.7, g/dL) 3.9 4.6 4.6 4.5
Albumin (3.4-4.8, g/dL) 2.4 3 2.5 3
Prothrombin time (0.88-1.16) 1.08 1.07 1.06 1.08
Partial thromboplastin time (0.85-1.18) 1.01 1 1.03 1.19
C3 (90-180) 20 56 59 99
C4 (10-40) 0 1 3 2
Cryoglobulins Present Absent Absent Present
Leucocytes (4.8-10.8, 103/mmc) 10670 3440 3400 3730
Hemoglobin (12-16, g/dL) 10.8 9.7 10.2 10.5
Platelets (130-400, 103/mmc) 313000 159000 153000 73000
AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; γGT: Gamma-glutamyl transpeptidase.
Figure 1  Purpuric rash with ulcers at the leg (patient 1).
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Figure 2  Biochemical/serological response to therapy (patient 1). HD: 
Haemodialysis; MP: High-dose methylprednisolone; PEX: Plasma-exchange; 
RTX: Rituximab. 
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mL/min per 1.73 m2). Active urinary sediment and 
nephrotic proteinuria persisted. Pulmonary aspergillosis 
was documented- medical plus supportive therapy was 
initiated and the patient recovered in a few weeks; 
however, he developed irreversible kidney failure and 
initiated dialysis acutely. He is currently doing well on 
maintenance hemodialysis (thrice weekly) treatment. 
DISCUSSION
We report here on two patients with rapidly progressive 
renal failure due to idiopathic proliferative GN who were 
resistant to conventional immunosuppressive therapy. 
Both the patients underwent rituximab treatment in 
off-label condition, RTX infusion was well tolerated by 
both the patients but sepsis developed over the follow-
up, fatal course occurring in patient 1. Numerous case 
reports and case series have suggested that the addition 
of rituximab to standard chemotherapy for malignant 
lymphoma increases the risk of viral infections such 
as varicella zoster[9], cytomegalovirus[10], HBV[11], 
parvovirus[12], and enteroviral encephalitis[13]. The risk of 
HBV reactivation has been added to the existing Boxed 
Warning of the rituximab label by the Food and Drug 
Administration in 2013[14]. Impaired immunity against 
non-viral pathogen agents such as Pneumocystis 
jirovecii[15] or cryptococcus[16] after rituximab therapy 
has been also noted.
A recent systematic review and meta-analysis has 
shown that rituximab plus standard chemotherapy 
for malignant lymphoma increases the incidence of 
severe leucopenia (RR = 1.24; 95%CI: 1.12-1.37) 
and granulocytopenia (RR = 1.07; 95%CI: 1.02-1.12) 
even if the overall risk of severe infections has not been 
increased (RR = 1.0; 95%CI: 0.87-1.14)[17]. We have 
already reported on a case of cholestatic hepatitis C 
after rituximab therapy for gastric cancer in a renal 
transplant recipient[18]. On the other hand, various 
authors have claimed that rituximab use for glomerular 
diseases is effective and has minimal adverse effects 
(Table 2)[1,19,20].
Our first patient presented idiopathic cryoglo-
bulinemic vasculitis which has undefined therapeutic 
management[21]. There is some evidence on the efficacy 
and tolerance of RTX in patients with HCV-associated 
mixed cryoglobulinemia vasculitis who were naïve, 
resistant or intolerant to antiviral therapy[22-25]. Two 
randomized controlled trials have compared RTX with 
conventional immunosuppressive therapy for HCV-
related mixed cryoglobulinemia vasculitis[26,27]. As listed 
in Table 3, evidence in the medical literature on RTX use 
among patients with non-infectious cryoglobulinemia 
vasculitis targeting kidneys is extremely limited, and 
a total of 16 cases were retrieved[28-37]. Patient 1 gives 
emphasis on the efficacy of RTX, as one RTX pulse 
made possible the control of renal disease: kidney 
function normalized, nephrotic syndrome disappeared 
and only nephritic urinary changes persisted. However, 
RTX use was complicated by sepsis a few weeks after 
medications. Medical and supportive therapy was 
unsuccessful and the patient ultimately expired due to 
septic shock (two months after RTX pulse). 
Patient 2
A 49-year-old Caucasian male underwent kidney biopsy 
for evaluation of serum creatinine 1.35 mg/dL [estimated 
glomerular filtration rate (eGFR) 56 mL/min per 1.73 m2
by MDRD equation], 3.2 g of proteinuria on 24-h urine 
collection and active urinary sediment (severe micro-
scopic hematuria with red blood cell casts). Renal biopsy 
showed global ialinosis in some glomeruli (5 out of 
14); the others had intense glomerular hypercellularity 
(mainly due to mesangial proliferation), a limited 
number of mesangial immune deposits and segmental 
thickening of glomerular basement membrane were 
also present. Final diagnosis was mesangial proliferative 
GN with immune deposits of unclear significance. Other 
pertinent chemistries were: negative cryoglobulins, 
normal rheumatoid factor and complement fractions; 
serum protein electrophoresis in the normal range. 
Serology tested negative for HBV, HCV and HIV markers, 
polymerase chain reaction was negative for HCV RNA. 
The search for anti-neutrophil cytoplasmic antibody 
(proteinase 3 and myeloperoxidase), anti-glomerular 
basement membrane antibody, extractable nuclear 
antigen antibody, antinuclear and anti-double stranded 
DNA tested negative. At discharge from the hospital, 
his medications included oral steroids, rabeprazole, 
amlodipine, doxazosine, furosemide, calcium carbonate, 
and darboepoetin. Partial remission of nephritic/nephrotic 
syndrome with improvement of kidney function (serum 
creatinine going back to 1.1 mg/dL) was obtained 
with intravenous methylprednisolone pulses, oral 
cyclophosphamide, azathioprine, and mycophenolate 
mofetil in variable associations. Eight years later, he 
was again admitted to our unit, showing bilateral lower-
extremity edema, arterial hypertension and serum 
creatinine of 2.9 mg/dL (eGFR 23 mL/min per 1.73 
m2 by MDRD equation). Nephrotic proteinuria was 
demonstrated (proteinuria of 9.2 g/d) with active urinary 
sediment. A repeat kidney biopsy revealed intracapillary/
extracapillary glomerular proliferation with several 
crescents and fibrinoid necrosis, diffuse arteriolosclerosis, 
in addition to uniform and diffuse thickening of the 
glomerular basement membrane. Immunofluorescence 
demonstrated sporadic and granular deposition of C1q/
C3 in the mesangium and capillary walls; fibrinogen in 
the Bowman space. Renal biopsy was complicated by 
perirenal hematoma and a few units of red packed cells 
were given. He received high-dose intravenous diuretic 
therapy with edema resolution and body weight loss, 
and intravenous methylprednisolone pulse therapy (500 
mg daily intravenous for three alternate days) with low-
dose oral steroids was not effective. Thus, one infusion 
of RTX (375 mg/m2) off-label was administered. One 
month after rituximab administration he was again 
hospitalized (acute pulmonary insufficiency with septic 
shock); serum creatinine of 4.56 mg/dL (eGFR, 11 
Fabrizi F et al . Rituximab for primary glomerulonephritis
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RTX pulse. On the basis of the evidence reported in 
Table 3, severe infections after RTX treatment are not 
uncommon [35% (6/17)]. 
RTX therapy in patients with nonviral cryoglo-
bulinemia vasculitis or membranoproliferative GN raises 
various questions such as the role of RTX as first-line 
or rescue therapy, the efficacy/safety of maintenance 
therapy with RTX, and the tolerance to RTX. In the 
absence of randomized controlled trials, such questions 
remain unanswered; as an example, the poor tolerance 
of our patients after RTX administration remains unclear. 
The French multicenter CryoVas survey retrospectively 
evaluated 242 patients with non-infectious mixed 
cryoglobulinemia vasculitis, RTX plus corticosteroids 
had greater therapeutic efficacy compared with 
corticosteroids alone and corticosteroids plus alkylating 
agents[38]. However, RTX plus corticosteroids was 
associated with more frequent infections than corti-
costeroids alone (HR = 9; 95%CI: 3.1-20, P < 0.001). 
Prospective data from the AIR (AutoImmunity and 
Rituximab) registry, which includes data on patients 
treated with rituximab off-label, have shown that 
among patients (n = 23) with nonviral cryoglobulinemia 
vasculitis on RTX, side-effects occurred in almost half 
of the patients (n = 11), including severe infections[34]. 
Infectious episodes were mostly reported in a patient 
subgroup (age > 70 years, essential type Ⅱ MC, GFR 
< 60 mL/min, and high-dose steroids) and were fatal 
in many (n = 3)[34]. Both our patients had important 
kidney impairment at baseline and concomitant therapy 
with intravenous high-dose corticosteroids, among other 
immunosuppressive agents. 
The current study calls for further research on the 
RTX-based treatment of essential cryoglobulinemic 
vasculitis or membranoproliferative GN but the low 
frequency of patients in individual centers would make 
Table 2  Literature review: Adverse events during rituximab therapy for primary membranous and membranoproliferative 
glomerulonephritis
Ref. n Rituximab treatment dose Follow-up period Concomitant therapy Response to RTX Side-effects after RTX
Fervenza et al[2]   15 1 g × 2, on days 1 and 15 12 mo ACE-I + ARB Complete (n = 2) or 
partial remission (n = 6)
Nonserious 
transient AE (n = 10) 
pneumonia (n = 1)
Segarra [3]   13 375 mg/m2 once weekly × 4 30 mo Tac (n = 10), CyA (n = 
3), CCS (n = 3)
Partial remission (n = 13) None
Fervenza et al[4]   20 375 mg/m2 once weekly × 4 24 mo ACE-I + ARB Complete (n = 4) or 
partial remission (n = 12)
Nonserious 
transient AE (n = 11) 
pneumonia (n = 1)
Michel et al[5]   28 375 mg/m2 once weekly × 2 or 3 or 4 (n 
= 27) 1 g × 2, on days 1 and 15 (n = 1)
12 mo ACE-I + ARB, CCS (n 
= 1), Tac (n = 1)
Complete (n = 6) or 
partial remission (n = 13)
Nonserious transient 
AE (few)
Ruggenenti et 
al[6]
100 375 mg/m2 once weekly × 4 29 mo CCS Complete (n = 27) or 
partial remission (n = 38) 
Nonserious transient 
AE (n = 28)
Dillon et al[7]     6 1 g × 2, on days 1 and 15 12 mo ACE-I + ARB Complete (n = 2) or 
partial remission (n = 3)
None
Kong et al[8]   13 500 mg × 1 (n = 6) 31.5 mo CCS (os) (n = 9) Remission (n = 19) Nonserious transient 
AE (n = 8)
500 mg × 2 (n = 3) CyA (n = 2) Pneumonia (n = 1)
500 mg × 4 (n = 4) CCS (iv) (n = 2)
ACE-I: Angiotensin converting enzyme inhibitors; AE: Adverse events; ARB: Angiotensin receptor blockers; CCS: Corticosteroids [by intravenous (iv) or 
oral (os) route]; CyA: Cyclosporine; MN: Membranous nephropathy; MPGN: Membranoproliferative glomerulonephritis; Tac: Tacrolimus; RTX: Rituximab. 
Table 3  Overview of cases with non-viral hepatitis mixed cryoglobulinemia (and kidney involvement) on rituximab
Ref. n Age (yr)/gender Treatment prior to RTX Features Response to RTX Side-effects after RTX
Arzoo et al[28] 1 71/F CS C, N, R Remission None
Ghijsels et al[29] 1 44/M CS, CPH, CHL C, Ca, R Remission None
Koukoulaki et al[30] 1 48/F CS, CPH GI, P, R Partial remission None
Bryce et al[31] 1 NA NA R No response None
Ruch et al[32] 1 64/M CS R Remission Cold agglutinine disease, sepsis
Annear et al[33] 1 42/F CS C, R Remission None
Terrier et al[34] 7 73 ± 5/M (n = 4) CS (n = 4) C (n = 6), N (n = 2), 
A (n = 2), R (n = 7)
Remission (n = 3), partial 
remission (n = 1), NA (n = 3)
Severe infections (n = 4)
Wink et al[35] 1 72/F CS, Aza C, P, R Remission None
Choudhry et al[36] 1 61/F CS, CPH C, P, R Remission None
Kamel et al[37] 1 77/F CS C, A, R Remission None
Own case 1 51/M CS, Aza C, GI, N, R Remission Severe infection
A: Arthralgias; Aza: Azathioprine; C: Cutaneous; Ca: Cardiac; CHL: Chlorambucil; CPH: Cyclophosphamide; CS: Corticosteroids; GI: Gastrointestinal; N: 
Neurological; NA: Not available; P: Pulmonary; R: Renal; RTX: Rituximab. 
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randomised controlled trials extremely difficult. Rituximab 
has surfaced as potential treatment option for some 
primary glomerular diseases and the HCV KDIGO Study 
Group[39] had already included rituximab among the 
recommended drugs (steroids, and cyclophosphamide) 
for the immunosuppressive treatment of HCV-associated 
kidney disease. The risks (and the predictive factors) of 
infections in kidney patients on RTX-therapy are not yet 
understood and are an area of active research. These 
patients should be monitored over the follow-up to avoid 
the occurrence of infectious episodes. 
COMMENTS
Case characteristics
Two male Caucasian patients with progressive kidney failure.
Clinical diagnosis
Arterial hypertension, bilateral lower-extremity edema. 
Differential diagnosis
Progressive kidney failure due to secondary glomerular disease.
Laboratory diagnosis
At presentation serum creatinine ranged between 2.5 and 2.9 mg/dL and 
proteinuria 3.6 and 9.2 g/d, microscopic haematuria with dysmorphic 
erythrocytes and red cell casts.
Imaging diagnosis
Computed tomography scan revealed normal sized kidneys bilaterally with 
normal echotexture in both the patients.
Pathological diagnosis
Renal biopsy (patient 2) showed intracapillary/extracapillary glomerular 
proliferation with several crescents and fibrinoid necrosis, in addition to uniform 
diffuse thickening of the glomerular basement membrane.
Treatment
Both the patients received one infusion of rituximab (375 mg/m2) off-label. 
Related reports
Various authors have claimed that rituximab use for glomerular diseases is 
effective and has minimal adverse effects.
Term explanation
Phase-contrast microscopy is a microscopy technique to analyze the 
morphology of urine erythrocytes. 
Experiences and lessons
The risks and the predictive factors of severe infections in kidney patients on 
rituximab therapy are still unclear and appear an area of active research.
Peer-review
It is a good article.
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